Trial Profile
Pilot Trial Studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients With Type II Diabetes and Insulin Resistance Undergoing Elective PTCA. A Randomized Double-Blinded Phase II Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Sponsors Takeda Pharma
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)
- 23 Jan 2009 Planned end date changed from 1 Dec 2008 to 1 Feb 2009 as reported by ClinicalTrials.gov.
- 23 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.